BIOMAT Database Logo BIOMAT Database Logo

Platelet aggregation inhibitors in prevention and treatment of coronary thrombosis. 2003

M E R Gomes, and F W A Verheugt
Department of Cardiology (540), Heart Centre, University Medical Centre, Geert Grooteplein Zuid 10, 6525 GA Nijmegen, the Netherlands.

Platelet aggregation plays a key role in the development of complications of atherosclerosis. By inhibiting platelet aggregation in a pharmacological way complications such as myocardial infarction and sudden death may be prevented. This goes for primary as well as secondary prevention. The most relevant substances for this goal are aspirin, clopidogrel and the new glycoprotein IIb/IIIa inhibitors.

UI MeSH Term Description Entries
D010975 Platelet Aggregation Inhibitors Drugs or agents which antagonize or impair any mechanism leading to blood platelet aggregation, whether during the phases of activation and shape change or following the dense-granule release reaction and stimulation of the prostaglandin-thromboxane system. Antiaggregants, Platelet,Antiplatelet Agent,Antiplatelet Agents,Antiplatelet Drug,Blood Platelet Aggregation Inhibitor,Blood Platelet Antagonist,Blood Platelet Antiaggregant,PAR-1 Antagonists,Platelet Aggregation Inhibitor,Platelet Antagonist,Platelet Antagonists,Platelet Antiaggregant,Platelet Antiaggregants,Platelet Inhibitor,Protease-Activated Receptor-1 Antagonists,Antiplatelet Drugs,Blood Platelet Aggregation Inhibitors,Blood Platelet Antagonists,Blood Platelet Antiaggregants,Platelet Inhibitors,Agent, Antiplatelet,Aggregation Inhibitor, Platelet,Antagonist, Blood Platelet,Antagonist, Platelet,Antiaggregant, Blood Platelet,Antiaggregant, Platelet,Drug, Antiplatelet,Inhibitor, Platelet,Inhibitor, Platelet Aggregation,PAR 1 Antagonists,Platelet Antagonist, Blood,Platelet Antiaggregant, Blood,Protease Activated Receptor 1 Antagonists
D003328 Coronary Thrombosis Coagulation of blood in any of the CORONARY VESSELS. The presence of a blood clot (THROMBUS) often leads to MYOCARDIAL INFARCTION. Thrombosis, Coronary,Coronary Thromboses,Thromboses, Coronary
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

M E R Gomes, and F W A Verheugt
[Vitamin K antagonists and platelet aggregation inhibitors in the prevention of thrombosis].
January 1977, Acta clinica Belgica,
M E R Gomes, and F W A Verheugt
[Secondary and primary prevention of coronary heart disease: platelet aggregation inhibitors and anticoagulants].
January 2002, Zeitschrift fur Kardiologie,
M E R Gomes, and F W A Verheugt
Ticagrelor, a platelet aggregation inhibitor for the potential prevention and treatment of arterial thrombosis and acute coronary syndromes.
May 2009, IDrugs : the investigational drugs journal,
M E R Gomes, and F W A Verheugt
Platelet inhibitors in the treatment of thrombosis.
January 1978, Clinical and investigative medicine. Medecine clinique et experimentale,
M E R Gomes, and F W A Verheugt
Platelet aggregation inhibitors in primary and secondary prevention of ischemic stroke.
April 2006, GMS health technology assessment,
M E R Gomes, and F W A Verheugt
[Thrombosis prevention with thrombocyte aggregation inhibitors in the venous system].
June 1982, Die Medizinische Welt,
M E R Gomes, and F W A Verheugt
Platelet Aggregation Tests and Thrombosis.
January 1969, Journal of the Royal College of Physicians of London,
M E R Gomes, and F W A Verheugt
Experimental thrombosis and prevention by drugs that interfere with platelet aggregation.
January 1970, Australasian annals of medicine,
M E R Gomes, and F W A Verheugt
Inhibitors of platelet function in the prevention of arterial thrombosis.
January 1975, Series haematologica (1968),
M E R Gomes, and F W A Verheugt
[Treatment with platelet aggregation inhibitors and additive proton pump inhibitors?]
July 2018, Der Internist,
Copied contents to your clipboard!